Peptides DB
Research-centric peptide and protocol reference hub

Vosoritide record · updated 7h ago

Skin & aestheticsHealing & recoveryGrade A · human clinicalResearch use only
All 34 studiesJump to the evidenceCompare
What is Vosoritide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: CNP analog, NPR-B receptor agonist

Primarily researched for · Skin & aestheticsRoute · Subcutaneous injection

Development stage

where Vosoritide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 19 registered trials. It describes the research record, not a recommendation.

Identity
NameVosoritide
Chain length—
Molecular weight4,103 Da
FormulaC176H290N56O51S3
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 119058036. No verified residue count for this compound.

Pharmacology
MechanismCNP analog, NPR-B receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 24, 2026. How this works →
Research stats
Total studies34
Human / animal / cellular21 / 4 / 1
Highest trial phasePhase 3
Years covered2018–2026
Latest study13d ago
Publication history
20182026
Research funding
—no NIH grants found
Safety signals
FAERS reports3
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

34 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Real-world evidence of vosoritide treatment in children under 2 years of age with achondroplasia in Colombia: a cases series
FindingMean age at last evaluation was 25.2 months (range 17–30 months).
Human2026Full text read0.80
Evaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.
FindingMedian total AHI was 3.2 events/hour in children receiving vosoritide and 6.9 in those not receiving treatment (p=0.105).
Human2026Full text read0.80
Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.
Findingp < 0.05 for nominal increases in RNFL thickness.
Human2023Full text read0.80
Growth plate senescence, chondrocyte biology, and the growth hormone-insulin-like growth factor 1 axis in childhood growth.
FindingNot reported in abstract.
review2026Full text read0.70
Vosoritide Treatment Does Not Change the Robust Bone Phenotype of Children with Achondroplasia
FindingNot reported in abstract.
Human2026Full text read0.80
A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.
Finding0.24 mg vosoritide administered, equivalent to 53 μg/kg.
Human2026Full text read0.80
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
FindingLSM difference of 2.33 cm/year between vosoritide and placebo; 95% CI, 1.85-2.82 cm/year; two-sided P<0.0001.
Human2023Full text read0.90
A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.
FindingLSM difference of 2.33 cm/year; 95% confidence interval, 1.85-2.82 cm/year; two-sided P<0.0001.
Human2023Full text read0.90
Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.
Finding74% of caregivers and 100% of children reported changes in daily activities.
Human2026Full text read0.70
From Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development.
TakeawayClinical pharmacology's integration of diverse data sources supports rare-disease drug development by informing key regulatory decisions.
review2026Full text read0.80
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design.
FindingNot reported in abstract.
Human2026Partial text0.50
Perceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.
FindingNot reported in abstract.
Human2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Vosoritide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Vosoritide is discussed should be drawn from it.

Articles mentioning Vosoritide